

## Supplementary Online Content

Clark CM, Schneider JA, Bedell BJ, et al, for the AV45-A07 Study Group. Use of florbetapir-PET for imaging  $\beta$ -amyloid pathology. *JAMA*. 2011;305(3):275-283.

**eTable.** Final neuropathological diagnosis for all 35 participants in the autopsy cohort

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable.** Final Neuropathological Diagnosis for All 35 Participants in the Autopsy Cohort

Age at death	Clinical Diagnosis	Final Neuropath Diagnosis
<b>Efficacy cohort (n=29)</b>		
81.5	AD <sup>1</sup>	AD
62.5	AD & IVD <sup>2</sup>	AD
73.9	AD	AD
86.2	AD	AD
84.6	AD	AD
104.3	AD	AD
87.4	AD	AD
55.9	AD	AD
88.7	AD	AD
70.1	AD	AD
93.2	Dementia NOS <sup>3</sup>	AD
69.3	AD	AD
85.9	AD	AD
86.8	AD	AD
88.2	AD	AD
91.7	MCI <sup>4</sup>	Control <sup>5</sup>
55.5	CN <sup>6</sup>	Control
60.0	CN	Control
72.1	CN	Control
85.7	CN	Control
99.9	CN	Control
92.2	MCI	Control
89.2	CN	Control
67.9	DLB <sup>7</sup>	AD
62.1	IVD	Hippocampal sclerosis
92.3	MCI	Neurofibrillary tangles & argyrophilic grains
88.1	AD	Neurofibrillary tangles, mesial temp lobe
76.3	PDD <sup>8</sup> & IVD	PD <sup>9</sup>
91.8	CN	Subcortical microscopic infarcts
<b>Front-runner participants (n=6)</b>		
48.0	PDD	AD
82.8	AD	AD
78.5	AD	AD
86.5	AD vs. IVD	AD
84.6	CN	Control
79.8	CN	Control

1 = Alzheimer's disease

2 = ischemic vascular dementia

3 = not otherwise specified

4 = mild cognitive impairment

5 = no neuropathology

6 = cognitively normal

7 = dementia with Lewy bodies

8 = Parkinson's disease dementia

9 = Parkinson's disease